Loading…
Orchestra BioMed Holdings, Inc. is projected to rise to $4.61 by 2027, a +16% move from its current price of $3.98. OBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.88 | $3.98 | $4.08 | +0.01% |
| Aug 4 | $3.84 | $3.98 | $4.13 | +0.03% |
| Aug 5 | $3.81 | $3.98 | $4.16 | +0.04% |
| Aug 6 | $3.79 | $3.98 | $4.19 | +0.05% |
| Aug 7 | $3.76 | $3.98 | $4.22 | +0.07% |
| Aug 8 | $3.74 | $3.98 | $4.24 | +0.08% |
| Aug 9 | $3.73 | $3.98 | $4.26 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.73 | $3.98 | $4.26 | +0.09% |
| Week 2 | $3.63 | $3.99 | $4.38 | +0.19% |
| Week 3 | $3.55 | $3.99 | $4.48 | +0.28% |
| Week 4 | $3.49 | $4.00 | $4.57 | +0.38% |
| Week 5 | $3.44 | $4.00 | $4.65 | +0.47% |
| Week 6 | $3.40 | $4.00 | $4.72 | +0.57% |
| Week 7 | $3.35 | $4.01 | $4.78 | +0.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. Its flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease.
Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Orchestra BioMed Holdings, Inc. (OBIO) is classified in the Healthcare sector and currently trades at $3.99 per share with a market cap of $238.92M, ranking 3468 in market size.
The price outlook is laid out in a year-by-year forecast showing a path of rising averages and notable upside over time. The 2026 forecast lists an average price of $3.99 with neutral sentiment, while the later years show a bullish trajectory, culminating in an average of $21.71 and a max of $39.50 by 2050, with a 444.2% ROI in that far horizon.
A major floor 24.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.8% below — buyers have tended to step in here.
The nearest ceiling, 19.3% above — a clean break opens room to run.
A major ceiling 31.7% above — clearing it would confirm fresh momentum.
Key OBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.89 | Buy | $3.90 | Buy |
| MA 10 | $3.79 | Buy | $3.85 | Buy |
| MA 20 | $3.81 | Buy | $3.86 | Buy |
| MA 50 | $3.95 | Buy | $3.94 | Buy |
| MA 100 | $4.10 | Sell | $4.01 | Sell |
| MA 200 | $4.15 | Sell | $4.01 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.73 | Neutral |
| Stoch RSI (14) | 97.19 | Sell |
| CCI (20) | 92.33 | Neutral |
| Williams %R (14) | -2.78 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 9.04 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 97.22 | Sell |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 72.77 | Sell |
| Momentum (10) | 0.30 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 3.98 | Buy |
| ADX (14) | 11.67 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture remains in a constructive range with a bullish overall tone. The RSI14 is 60, and price action sits around the 50-day moving average. The 50-day simple moving average is $3.95 and the 200-day simple moving average is $4.15.
The stock shows a defined support at $3.63 and a resistance at $4.75. Over the last 30 days, the price has traded between $3.36 and $4.74, indicating a relatively tight range with upside potential if momentum remains positive.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $3.98 | $5.21 | 0% | Neutral | |
| $3.70 | $4.61 | $6.05 | +16% | Neutral | |
| $4.24 | $5.42 | $7.37 | +36% | Bullish | |
| $4.68 | $6.12 | $8.56 | +54% | Bullish | |
| $4.53 | $6.02 | $8.63 | +51% | Bullish | |
| $4.70 | $6.36 | $9.29 | +60% | Bullish | |
| $4.87 | $6.70 | $9.96 | +68% | Bullish | |
| $4.97 | $6.95 | $10.50 | +75% | Bullish | |
| $6.03 | $8.54 | $13.11 | +115% | Bullish | |
| $6.55 | $9.41 | $14.65 | +136% | Bullish | |
| $8.33 | $12.71 | $20.99 | +219% | Bullish | |
| $12.62 | $21.37 | $38.44 | +437% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.49 | $3.98 | $4.87 | +0.00% |
| September 2026 | $3.50 | $4.13 | $5.00 | +3.68% |
| October 2026 | $3.39 | $4.03 | $4.93 | -2.35% |
| November 2026 | $3.38 | $4.03 | $4.98 | +0.08% |
| December 2026 | $3.50 | $4.19 | $5.21 | +3.99% |
Click any year to see its month-by-month OBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OBIO to range from $3.49 to $5.21 through 2026. The $3.98 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OBIO price prediction for 2027 points to an average of $4.61 (low $3.70, high $6.05) — a potential gain of +16% on today's $3.98. A consolidation phase looks the most probable path here.
In 2028, OBIO is projected to trade between $4.24 and $7.37, averaging $5.42 — a potential gain of +36% from today's $3.98. That is up +18% on the projected 2027 average. Momentum favours further upside here.
Orchestra BioMed Holdings, Inc.'s 2029 outlook centres on $6.12, within a $4.68 to $8.56 range. That is up +13% on the projected 2028 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, OBIO could reach as high as $8.63, with a base case around $6.02 and support toward $4.53 — roughly +51% from $3.98. Momentum favours further upside here.
Expect OBIO to range from $4.70 to $9.29 through 2031. The $6.36 average target implies a +60% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OBIO price prediction for 2032 points to an average of $6.70 (low $4.87, high $9.96) — a potential gain of +68% on today's $3.98. Momentum favours further upside here.
In 2033, OBIO is projected to trade between $4.97 and $10.50, averaging $6.95 — a potential gain of +75% from today's $3.98. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Orchestra BioMed Holdings, Inc.'s 2034 outlook centres on $8.54, within a $6.03 to $13.11 range. That is up +23% on the projected 2033 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2035, OBIO could reach as high as $14.65, with a base case around $9.41 and support toward $6.55 — roughly +136% from $3.98. Buyers look set to stay in control over this stretch.
Expect OBIO to range from $8.33 to $20.99 through 2040. The $12.71 average target implies a +219% move from current prices. That is up +35% on the projected 2035 average. Momentum favours further upside here.
The OBIO price prediction for 2050 points to an average of $21.37 (low $12.62, high $38.44) — a potential gain of +437% on today's $3.98. Buyers look set to stay in control over this stretch.
Investing $1,000 in OBIO today (≈ 251.256281 OBIO) could be worth
$5,369.25
+$4,369.25 (+437%) by 2050 · US Dollar
Based on the average projected OBIO price of $21.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OBIOwould be worth at today's price.
$1,000 invested in OBIO on Jul 31, 2025 (≈ 326.797392 OBIO) would be worth
$1,300.65
+$300.65 (+30.1%) today · 1.30× · US Dollar
Based on a OBIO entry price of $3.06 vs. today's $3.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.74 | $1,064.17 | +6.4% |
| 1 month ago | $4.3 | $925.58 | -7.4% |
| 3 months ago | $3.97 | $1,002.52 | +0.3% |
| 6 months ago | $4.02 | $990.05 | -1.0% |
| 1 year ago | $3.06 | $1,300.65 | +30.1% |
| All time (5.0y) ago | $9.93 | $400.81 | -59.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OBIO forecast.
Our base-case forecast reaches $8.00 around 2034.
Implied market cap at $8.00: $479.05M
The multi-year forecast points to a steady uptrend in average prices and rising ROIs. For 2027 the avg is $4.63 with a 16.1% ROI and neutral sentiment, followed by 2028 at $5.47 (37.2%), 2029 at $6.19 (55.2%), and 2030 at $6.07 (52.2%), all with bullish sentiment. The trajectory continues with 2031 at $6.43 (61.1%), 2032 at $6.77 (69.6%), 2033 at $7.00 (75.5%), 2034 at $8.68 (117.6%), and 2035 at $9.57 (139.8%).
Longer horizon forecasts show stronger upside: 2040 average $12.95 with a 224.6% ROI, and by 2050 average $21.71 with a 444.2% ROI, all labeled bullish. These figures are estimates and not guarantees, and actual results may differ. The implied path suggests growing value over time with substantial upside in the outer years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $6.07, with a minimum of $4.54 and a maximum of $8.75, and an ROI of 52.2%, with bullish sentiment.
The forecast shows rising averages and ROIs through 2050, including an average of $12.95 in 2040 and $21.71 in 2050 with a 224.6% and 444.2% ROI respectively, and bullish sentiment in later years. Note that these are estimates and not guarantees.
Yes, the 2050 forecast lists a max of $39.50, with an average of $21.71 and a min of $12.63, and a 444.2% ROI.
Current price is $3.99 and the market cap is $238.92M.
The 2040 forecast lists an average price of $12.95, a minimum of $8.40, a maximum of $21.59, and a ROI of 224.6%, with bullish sentiment.
Orchestra BioMed Holdings, Inc. Community Discussion
0Share your Orchestra BioMed Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.